Peng Z et al., A droplet reactor on a super-hydrophobic surface allows control and characterization of amyloid fibril growth Communications Biology September 2020 10.1038/s42003-020-01187-7

 SH Lee et al., Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement. Cell Reports August 2016 10.1016/j.celrep.2016.06.099

 A Chakraborty et al., Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways. Molecular Psychiatry March 2014 10.1038/mp.2013.21

 Absalon Sabrina et al., MiR-26b, Upregulated in Alzheimer's Disease, Activates Cell Cycle Entry, Tau-Phosphorylation, and Apoptosis in Postmitotic Neurons Journal of Neuroscience September 2013 10.1523/JNEUROSCI.1327-13.2013

 Kawakami Fumitaka et al., Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β FEBS Journal November 2013 10.1111/febs.12579

 Kawakami Fumitaka et al., Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β FEBS Journal October 2011 10.1111/j.1742-4658.2011.08389.x

 Coutadeur Severine et al., A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro Journal of Neurochemistry May 2015 10.1111/jnc.13018

 CJ Dunning et al., Direct High Affinity Interaction between Aβ42 and GSK3α Stimulates Hyperphosphorylation of Tau. A New Molecular Link in Alzheimer's Disease? ACS Chemical Neuroscience February 2016 10.1021/acschemneuro.5b00262

 Kawakami Fumitaka et al., LRRK2 Phosphorylates Tubulin-Associated Tau but Not the Free Molecule: LRRK2-Mediated Regulation of the Tau-Tubulin Association and Neurite Outgrowth PLoS One January 2012 10.1371/journal.pone.0030834

 Frost Danielle et al., β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites PLoS One May 2011 10.1371/journal.pone.0019264

  et al., N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases Brain August 2022

  et al., Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease EBioMedicine February 2022

  et al., Tau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation Nature Communications November 2021

  et al., P?tau235: a novel biomarker for staging preclinical Alzheimer’s disease EMBO Molecular Medicine November 2021

  et al., Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nature medicine August 2021

  et al., Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70 Brain February 2021

  et al., Head?to?head comparison of clinical performance of CSF phospho?tau T181 and T217 biomarkers for Alzheimer's disease diagnosis Alzheimer's & Dementia November 2020

  et al., Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in A? pathology are detected EMBO Molecular Medicine November 2020

  et al., Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline Acta Neuropathologica July 2020

  et al., Brain Brain March 2023